Xeinadin acquires Graham Paul  

Date:

Category:

Share this article:

Xeinadin, one of the leading professional services firms in the UK and Ireland, has announced the acquisition of Welsh accountancy firm, Graham Paul.  

Graham Paul is a Welsh accountancy firm with over 70 years experience servicing clients in the agricultural, healthcare and legal sectors as well as family-owned businesses and SMEs. The team is over 30 people strong across two offices in Bridgend and Cardiff.  

Xeinadin is a firm of business advisory and accountancy practices in over 100 locations across the UK and Ireland that provides over 40 service lines to over 50,000 clients, predominantly small and medium-sized businesses and their owner-managers.  

Graham Paul’s acquisition brings particular strength to Xeinadin’s healthcare offering, as well as bolstering access to experts in Wales. The firm has a full suite of services from audit and assurance to tax and planning.  

Xeinadin is a fast-growing, acquisitive firm which has already made 4 acquisitions this year, as one of the professional services market’s leading disrupters. The growth of the firm follows a significant minority investment from private equity firm Exponent earlier this year. 

Derry Crowley, CEO, Xeinadin, said: “We are pleased to announce that Graham Paul is joining Xeinadin. It will provide additional expertise in some of our key sectors such as healthcare and family-owned businesses and we are looking forward to integrating them into the Xeinadin family.” 

Nigel Williams, Director, Graham Paul, said: “Through joining Xeinadin, Graham Paul will continue to deliver the high standard of professional service for which we have become known. Being part of a dynamic larger organisation will allow us to support our clients even better with more services and greater expertise, and also embrace new opportunities for the firm. We are looking forward to our future as part of Xeinadin.

This website uses cookies

With these cookies, we and third parties can collect information about you and your internet behaviour, both within and outside our website. Based on this, we and third parties adjust the website, our communication, and advertisements to your interests and profile. You can read more information in our cookie statement.

If you opt for acceptance, we will place all cookies. If you opt for rejection, we will only place functional and analytical cookies. You can adjust your preferences at a later time.

Accept Reject More options

This website uses cookies

With these cookies, we and third parties can collect information about you and your internet behaviour, both within and outside our website. Based on this, we and third parties adjust the website, our communication, and advertisements to your interests and profile. You can read more information in our cookie statement.

Functional cookies
Arrow down

Functional cookies are essential for the proper functioning of our website. They allow us to enable basic functions such as page navigation and access to secure areas. These cookies do not collect personal information and cannot be disabled.

Analytical cookies
Arrow down

Analytical cookies help us gain insight into how visitors use our website. We collect anonymised data about page interactions and navigation, enabling us to continuously improve our site.

Marketing cookies
Arrow down

Marketing cookies are used to track visitors when they visit different websites. The goal is to display relevant advertisements to the individual user. By allowing these cookies, you help us show you relevant content and offers.

Accept all Save

Name

Subtitle
Developer
Location
They are focussed on creating a future-focused and relationship-driven culture, that keeps its promises to you, our team members, and partners.
Xeinadin